Efficacy and Safety of Rebamipide versus Its New Formulation, AD-203, in Patients with Erosive Gastritis: A Randomized, Double-Blind, Active Control, Noninferiority, Multicenter, Phase 3 Study.
Gwang Ha KimHang Lak LeeMoon Kyung JooHong Jun ParkSung Woo JungOk Jae LeeHyung Kil KimHoon Jai ChunSoo Teik LeeJi Won KimHan Ho JeonIl-Kwun ChungHyun Soo KimDong Ho LeeKyoung Oh KimYun Jeong LimSeun Ja ParkSoo-Jeong ChoByung-Wook KimKwang Hyun KoSeong Woo JeonJae-Gyu KimIn-Kyung SungTae Nyeum KimJae Kyu SungJong-Jae ParkPublished in: Gut and liver (2021)
The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (MucostaⓇ) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.